Clinical trials
Phase 3 Lung Neoplasms trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
62 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 3 |
| 2011 | 1 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 5 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 6 |
| 2024 | 6 |
| 2025 | 5 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 21 |
| Recruiting | 14 |
| Unknown status | 12 |
| Active, not recruiting | 10 |
| Terminated | 3 |
| Not yet recruiting | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 5 |
| Bristol-Myers Squibb | 4 |
| Merck Sharp & Dohme LLC | 4 |
| Amgen | 2 |
| Fudan University | 2 |
| Guangdong Association of Clinical Trials | 2 |
| Jiangsu HengRui Medicine Co., Ltd. | 2 |
| Novartis Pharmaceuticals | 2 |
| Pfizer | 2 |
| Sanofi | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lung Neoplasms | 62 |
| Carcinoma, Non-Small-Cell Lung | 26 |
| Carcinoma | 5 |
| Lung Diseases | 5 |
| Neoplasms | 5 |
| Thoracic Neoplasms | 5 |
| Bronchial Neoplasms | 4 |
| Carcinoma, Bronchogenic | 4 |
| Respiratory Tract Diseases | 3 |
| Respiratory Tract Neoplasms | 3 |
Trials
Showing 1 to 25 of 62. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.